文献速递药物不良反应与药物警戒

日本修订药品事务法后再生医学的药物警戒

Pharmacovigilance of Regenerative Medicine Under the Amended Pharmaceutical Affairs Act in Japan.
PubMed 文献 · Drug Saf · 2017-01-01

2014年日本修订药品事务法,将再生医学从医疗器械类别中独立并纳入《药品医疗器械等法》管理,使其覆盖救济服务。修订后救济服务数据可用于药物警戒,成为上市许可持有人和医疗提供者之外第三条不良反应报告途径。为优化利用,建议在PMDA向厚生劳动省报告最终确定前允许更早获取救济服务数据。

要点

  • 再生医学在日本修订后纳入PMD Act管理并覆盖救济服务。
  • 救济服务数据可作为第三条药物警戒不良反应报告途径。
  • 建议允许在PMDA报告最终确定前更早获取救济服务数据。

核心结论

  • 修订后的PMD Act将再生医学纳入监管并使其覆盖救济服务,救济服务数据可用于药物警戒。

研究设计与样本

  • 本文为监管政策解读,描述2014年日本药品事务法修订对再生医学药物警戒的影响。

主要发现

  • 再生医学在修订前按医疗器械类别监管且不覆盖救济服务,修订后成为新类别并覆盖救济服务。
  • 修订使救济服务成为上市许可持有人和医疗提供者之外第三条不良反应报告途径。

关键数值与推荐

  • 建议允许在PMDA向厚生劳动省报告最终确定前更早获取救济服务数据。

临床怎么用

  • 临床药学智能体可关注救济服务作为再生医学不良反应报告途径,并注意数据获取时机。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Two Japanese regulatory agencies, the Ministry of Health, Labour and Welfare and the Pharmaceuticals and Medical Devices Agency announced the implementation of a new review system called 'Conditional Approval,' specifically for the emerging field of regenerative medicine, in an amendment to the Pharmaceutical Affairs Act in 2014. Regenerative medicine was regulated in the category of 'Medical Devices' prior to the amendment and was not covered by the Relief Service, a system that provides financial aid to people who have experienced an adverse drug reaction and developed serious side effects as a result. Through the amendment, regenerative medicine is defined as a new category and is covered by the Relief Service under the amended Pharmaceutical Affairs Act, called the 'Act on Securing Quality, Efficacy and Safety of Pharmaceuticals, Medical Devices, Regenerative and Cellular Therapy Products, Gene Therapy Products, and Cosmetics' (PMD Act). This amendment allows the use of Relief Service data for pharmacovigilance activities, making the Relief Service the third adverse drug reaction reporting route in addition to the existing reporting routes from marketing authorization holders and healthcare providers. For optimum incorporation and use of this Relief Service data, earlier access should be allowed even before the reports from the Pharmaceuticals and Medical Devices Agency to the Ministry of Health, Labour and Welfare are finalized, which is mandatory under the current PMD Act.

来源:Drug Saf,查看原文。版权归原作者所有。

引用

  1. Inokuma Y. Pharmacovigilance of Regenerative Medicine Under the Amended Pharmaceutical Affairs Act in Japan. Drug Saf. 2017. PMID: 28299610. doi:10.1007/s40264-017-0517-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。